Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adaptor protein complex 4 subunit beta-1 is a component of the AP-4 heterotetrameric complex, which also includes the subunits ε (epsilon), μ4 (mu-4), and σ4 (sigma-4). AP-4 complex plays an essential role in the sorting and intracellular trafficking of specific membrane proteins from the trans-Golgi network to endosomal compartments. The AP-4 complex is structurally related to other adaptor complexes (AP-1, AP-2, AP-3) but has unique features, such as a truncated beta-appendage[4]. The AP-4 complex is required for normal brain development and neuronal function, with mutations or deficiency in its subunits (including AP4B1) causing severe intellectual disability and progressive spastic paraplegia[1][6]. Currently, AP4B1 is not considered a classical therapeutic target such as a receptor, enzyme, or transporter, and there are no known drugs that target this protein directly. The primary clinical relevance of AP4B1 is its role in certain hereditary neurodevelopmental disorders[1][6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adaptor protein complex 4 subunit beta-1 (AP4B1).